← Back to Search

Nucleoside Analogue

ATI-2173 50 mg Non-Asian for Chronic Hepatitis B

Phase 1
Waitlist Available
Research Sponsored by Antios Therapeutics, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through the end of study, average of 3 months
Awards & highlights

Summary

This trial is testing a new drug called ATI-2173 in healthy Japanese, Chinese, and Non-Asian people. The researchers want to see how the drug moves through the body, if it is safe, and if people can take it without significant side effects. They are also checking if food affects how the drug works in Non-Asian participants.

Eligible Conditions
  • Chronic Hepatitis B

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through the end of study, average of 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through the end of study, average of 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
AUC0-inf ATI-2173, clevudine, and M1 in plasma
AUC0-t ATI-2173, clevudine, and M1 in plasma
Ae of ATI-2173, clevudine, and M1 in urine
+7 more
Secondary outcome measures
AUC0-72 of ATI-2173, clevudine, and M1 in plasma for food effect
AUC0-inf of ATI-2173, clevudine, and M1 in plasma for food effect
Cmax of ATI-2173, clevudine, and M1 in plasma for food effect
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: ATI-2173 50 mg Non-AsianExperimental Treatment1 Intervention
Healthy adult non-Asian subjects will receive 50 mg of ATI-2173
Group II: ATI-2173 50 mg JapaneseExperimental Treatment1 Intervention
Healthy adult Japanese subjects will receive 50 mg of ATI-2173
Group III: ATI-2173 50 mg ChineseExperimental Treatment1 Intervention
Healthy adult Chinese subjects will receive 50 mg of ATI-2173
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ATI-2173 50 mg
2021
Completed Phase 1
~40

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Antios Therapeutics, IncLead Sponsor
5 Previous Clinical Trials
198 Total Patients Enrolled
~11 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top